Skip to content

Comparison of standard triple drugs therapy and sequential regimen for Helicobacter- pylori eradication

Comparison of standard triple drugs therapy and sequential regimen for Helicobacter- pylori eradication

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201104226030N5
Enrollment
140
Registered
2011-07-08
Start date
2011-02-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspepsia. Dyspepsia

Interventions

Intervention 1: Patients in the second group (intervention) were treated by omeprazole capsule 20 mg for 14 days, Amoxicillin capsule 1 gr BD for 5 days, then clarithromycin tablet 500 mg and Tinidaz
Treatment - Drugs
Patients in the second group (intervention) were treated by omeprazole capsule 20 mg for 14 days, Amoxicillin capsule 1 gr BD for 5 days, then clarithromycin tablet 500 mg and Tinidazole tablet 500 m
The patients in the first group (control) were treated by triple standard therapy (omeprazole capsule 20 mg BID, Amoxicillin capsule 1 gr BID, clarithromycin tablet 500mg BID for 14 days)

Sponsors

Vice-chancellor for research of Hamadan university of medical sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria : patients in whom Helicobacter pylori infection was detected by endoscopic method, serology, and urease breathe test with C14. Exclusion criteria: past history of Helicobacter pylori infection treatment , upper gastero- intestinal surgery, Gasteric cancer, renal or liver failure, breast feeding & pregnant woman.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Eradication of Helicobacter pylori. Timepoint: 4-6 weeks after treatment. Method of measurement: Rate of eradication by Urease breathe test with C14.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Bahram Garmrudi Nejhad Rostami

Hamadan university of medical sciences

b.garmrudi@umsha.ac.ir+98 81 1838 0704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026